DEVELOPMENT OF A LIVE ATTENUATED HSV-2 VACCINE

生殖器疱疹是一种常见的生殖器疾病。 这些感染的流行率是显着的， 尽管有有效的抗病毒药物，这种增长使年轻人 和婴儿生殖器疱疹和新生儿疱疹的风险。新生儿 疱疹感染与神经损伤和高死亡率有关。 此外，活跃的生殖器疱疹病变促进艾滋病毒的传播。 大部分传播是由于无症状脱落， 需要一种有效的预防性疫苗，以减少生殖器感染的传播， 疱疹，从而降低新生儿疱疹的发病率。最近的一个研究所 关于21世纪疫苗优先事项的报告强调了需要 生殖器疱疹的治疗方法有哪些阿维龙建议开发 预防HSV-2疾病的减毒活疫苗。一种减毒活病毒， 缺乏γ 134.5基因的两个拷贝的重组HSV-2病毒， 构建了UL 55、UL 56和US 10-US 12。该重组体高度 神经衰减的和遗传稳定的。在此期间，该病毒将 在豚鼠生殖器疱疹模型中评估安全性和有效性。在 此外，进一步的体外表征将使高质量的临床 为IND生产的试验材料，使灵长类动物研究和早期阶段 我是人体试验。 拟定商业应用： 不可用

DESCRIPTION: (Adapted from Applicant's Abstract) Genital herpes is a major health problem in the U.S. The prevalence of these infections is dramatically increasing despite effective antiviral drugs. This increase puts young adults and infants at risk of genital and neonatal herpes, respectively. Neonatal herpes infections are associated with neurologic impairment and high mortality. In addition, active genital herpes lesions facilitate the transmission of HIV. Much of the transmission is due to asymptomatic shedding which highlights the need for an efficacious prophylactic vaccine to reduce the spread of genital herpes and thereby reduce the incidence of neonatal herpes. A recent Institute of Medicine report on vaccine priorities for 21st century highlights the need for a safe and effective vaccine for genital herpes. Aviron proposes to develop a live attenuated vaccine to prevent HSV-2 disease. A live, attenuated, recombinant HSV-2 virus lacking both copies of gamma1 34.5 gene in addition to UL55, UL56, and US10-US12 was constructed. This recombinant was highly neuroattenuated and genetically stable. During this proposal this virus will be evaluated in the guinea pig model of genital herpes for safety and efficacy. In addition further in vitro characterization will enable high quality clinical trial material to be produced for IND enabling primate studies and early Phase I human trials. PROPOSED COMMERCIAL APPLICATION: Not Available